Drug Index



Mechanism :

Indinavir inhibits the HIV viral protease enzyme which prevents cleavage of the gag-pol polyprotein, resulting in non-infectious, immature viral particles.

Indication :

• Treatment of HIV-1 infection in combination with reverse transcriptase inhibitor (RTI) nucleoside analogues.

Contraindications :

In patients with clinically significant hypersensitivity to any of its components.

Dosing :

4 to 15 years: 234 to 500 mg/sqm thrice a day. Administer with water, 1 hour before or 2 hours after a meal.

Safety and efficacy is not established in neonates and infants.

Adverse Effect :

Increased spontaneous bleeding in patients with haemophilia, liver function abnormalities, pancreatitis; dyspepsia, arthralgia, new onset diabetes mellitus, exacerbation of pre-existing diabetes mellitus, hyperglycemia, anaphylactoid reactions, urticaria, vasculitis, depression, oral paraesthesia, rash including erythema multiforme and Stevens-Johnson syndrome, hyperpigmentation, alopecia, paronychia, ingrown toenails, pruritus, redistribution/accumulation of body fat, urolithiasis, nephrolithiasis, increased serum cholesterol, increased serum triglycerides, myocardial infarction.

Interaction :

CYP3A4 Drugs: Indinavir is an inhibitor of the cytochrome P450 isoform CYP3A4. Coadministration with drugs primarily metabolized by CYP3A4 may result in increased plasma concentrations of the other drug, which could increase or prolong its therapeutic and adverse effects. Indinavir is metabolized by CYP3A4. Drugs that induce CYP3A4 activity would be expected to increase the clearance of indinavir, resulting in lowered plasma concentrations of indinavir. Coadministration of drugs that inhibit CYP3A4 may decrease the clearance of indinavir and may result in increased plasma concentrations of indinavir.
Dosage adjustments for indinavir when administered in combination therapy:
Delavirdine, Itraconazole, or Ketoconazole: Reduce indinavir dose to 600 mg every 8 hours.
Efavirenz: Increase indinavir dose to 1000 mg every 8 hours.
Lopinavir and Ritonavir: Indinavir 600 mg twice daily.
Nevirapine: Increase indinavir dose to 1000 mg every 8 hours.
Rifabutin: Reduce rifabutin to 1/2 the standard dose plus increase indinavir to 1000 mg every 8 hours.
Ritonavir: Adjustments necessary for both agents:
Ritonavir 100-200 mg twice daily plus indinavir 800 mg twice daily or
Ritonavir 400 mg twice daily plus indinavir 400 mg twice daily.

Renal Dose :

Dose in Renal Impairment GFR (mL/min)
20-50Dose as in normal renal function Monitor closely
10-20Dose as in normal renal function Monitor closely
<10Dose as in normal renal function Monitor closely

Dose in Patients undergoing Renal Replacement Therapies
CAPDUnlikely to be dialysed. Dose as in GFR<10 mL/min
HDNot dialysed. Dose as in GFR<10 mL/min
HDF/High fluxNot dialysed. Dose as in GFR<10 mL/min
CAV/VVHDUnlikely to be dialysed. Dose as in GFR=10–20 mL/min

Hepatic Dose :

For Adults
Mild and moderate hepatic impairment: Reduce the recommended dose to 600 mg PO every 8 hours.
Dose in severe hepatic impairment has not been studied.
08/05/2020 08:50:45 Indinavir
ask a doctor
Ask a Doctor
Disclaimer: The information given by www.pediatriconcall.com is provided by medical and paramedical & Health providers voluntarily for display & is meant only for informational purpose. The site does not guarantee the accuracy or authenticity of the information. Use of any information is solely at the user's own risk. The appearance of advertisement or product information in the various section in the website does not constitute an endorsement or approval by Pediatric Oncall of the quality or value of the said product or of claims made by its manufacturer.
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0